Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 5;50(4):1462–1466. doi: 10.4143/crt.2017.473

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 by the Korean Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 1. — The patient achieved complete remission 30 days after chimeric antigen receptor T-cell strategy targeting CD19 (CART19s) infusion with grade 2 cytokine release syndrome. (A) Positron emission tomography/computed tomography (PET/CT) showed lymphoma activities in the terminal ileum, the mesentery lymph nodes, the pancreatic tail, the left femur and the vertebral body of S2 pre-CART19 treatment. (B) PET/CT showed a complete remission 30 days post-CART19 treatment. (C) The patient developed fever 6 hours after CART19 infusion with the highest temperature 40.8°C and decreased to normal level after 5 days. (D) Serum levels of interleukin (IL)-6, IL-10, interferon γ (IFN-γ), C-reactive protein (CRP), D-dimer, and ferritin were elevated 2 days after the infusion and fell into the normal range within 4 days with supportive care.